Abstract: Tapentadol may have a lower abuse risk than other opioids because it has a relatively low affinity for the mu-opioid receptor. The aim of this retrospective cohort study was to compare the risk of opioid abuse between tapentadol immediate release (IR) and oxycodone IR using 2 claims databases (Optum and MarketScan). Subjects with no recent opioid use exposed to tapentadol IR or oxycodone IR in 2010 were followed for 1 year. The outcome was the proportion of subjects who developed opioid abuse, defined as subjects with International Classification of Diseases, 9th revision, codes for opioid abuse, addiction, or dependence. The relative odds of abuse were estimated using a logistic regression model with propensity-score stratification. The estimates from the 2 databases were pooled using a random effects model. There were 13,814 subjects in Optum (11,378 exposed to oxycodone, 2,436 exposed to tapentadol) and 25,553 in MarketScan (21,728 exposed to oxycodone, 3,825 exposed to tapentadol). The risk of abuse was higher in the oxycodone group than in the tapentadol group in each database. The pooled adjusted estimate for the odds of abuse was 65% lower with tapentadol than with oxycodone (odds ratio = .35, 95% confidence interval = .21-.58). The risk of receiving an abuse diagnosis with tapentadol was lower than the risk with oxycodone. Continued monitoring is warranted because opioid desirability can change over time.
T he burden of pain is a significant public health problem. The Institute of Medicine reported in 2011 that chronic pain affects millions of adults in the United States, more than the total affected by heart disease, cancer, and diabetes combined, 17 and that uncontrolled pain substantially reduces quality of life and productivity. 17 Opioids are increasingly prescribed for the treatment of painful chronic conditions, 20 but there is growing concern about the risk of opioid abuse, diversion, 10,20 overdose, and death. 3, 32, 36, 40 The mechanism of action of an opioid could influence its risk of abuse. 21, 43, 44 Tapentadol is an opioid with 2 mechanisms of action; it activates opioid receptors and inhibits the reuptake of norepinephrine. 19 Tapentadol has an 18-fold lower affinity for the mu-opioid receptor than morphine. 39 Because the activation of the muopioid receptor is responsible for the mood alterations and the euphoria associated with opioids, the risk of abuse associated with tapentadol may be expected to be lower than with other opioids. Limited evidence from population-based studies also suggests that the risk of abuse of tapentadol may be lower than other opioids. Opioid doctor shopping, that is, obtaining opioid prescriptions from multiple prescribers, 7, 8 which is a way in which opioids may be abused and their use diverted, 3, 26, 35 is much less commonly observed in opioid-na€ ıve subjects initially exposed to tapentadol than in opioid-na€ ıve subjects initially exposed to oxycodone. 9 Similarly, data from internet monitoring, surveillance of addiction treatment centers, pharmacovigilance efforts, and surveys of college students suggest that the risk of abuse of tapentadol is lower than that of other Schedule II opioids. 11, 12 However, there are no studies that explicitly compare the risk of opioid abuse and addiction in subjects prescribed tapentadol versus oxycodone. Therefore, we sought to compare the risk of opioid abuse between tapentadol immediate release (IR) and oxycodone IR.
Methods
We conducted a retrospective cohort study using 2 U.S. claims databases (Optum and MarketScan), which are commonly used for pharmacoepidemiologic research. The Optum Clinformatics database represents a privately insured population and captures administrative claims primarily from the UnitedHealth Group; it has at least 36 million members with both medical and pharmacy benefits. The MarketScan Commercial Claims and Encounters database represents a privately insured population and captures administrative claims from inpatient and outpatient visits and pharmacy claims of large employers and multiple insurance plans. The data set used for this study contains more than 90 million individuals with medical and pharmacy coverage from January 2000 to January 2012.
Inclusion Criteria
Subjects with no recent opioid use whose first opioid exposure was to tapentadol IR or oxycodone IR in 2010 were included and observed for 1 year. Subjects with no recent opioid use were those with no opioid dispensing during the 3 months before the index date. The index date was the date of the first dispensing of tapentadol or oxycodone. Subjects were required to have been in the database for at least 3 months prior to their index date and for at least 12 months after. The codes used to identify tapentadol IR and oxycodone IR are listed in Appendix 1.
One year of follow-up was selected because studies assessing shopping behavior suggest that 75% of the subjects who developed shopping behavior had the first event #261 days after first exposure with a median of 234 days. 8 
Exclusion Criteria
Subjects with a history of opioid abuse, opioid addiction, or opioid dependence at any time before the index date, as well as subjects who filled a prescription for an opioid other than the indexed opioid before the index date or within the next 3 days, were excluded.
Outcome
The outcome of interest was incident reported diagnosis of opioid abuse, opioid addiction, or opioid dependence after the index date. The list of the International Classification of Diseases, 9th revision (ICD-9), Healthcare Common Procedure Coding System, and Current Procedural Terminology codes used is found in Table 1 .
Confounders
To control for the effect of baseline differences between the subjects exposed to tapentadol and those exposed to oxycodone, propensity score stratification was used. Propensity score is the conditional probability of a subject's receiving a particular exposure, in this case, initial exposure to tapentadol versus oxycodone, given a set of confounders. To calculate the propensity score, the confounders were included in a logistic regression model to predict the exposure, without including the outcome. 5, 6 As a result, the collection of confounders was collapsed into a single variable, the probability (propensity) of being initially exposed to tapentadol versus oxycodone. Subjects initially exposed to tapentadol and subjects initially exposed to oxycodone who have the same value of propensity score (regardless of the treatment they actually received) will have the same probability of receiving one initial treatment or the other.
Propensity Score
It has been shown that models that automatically select the variables to calculate the propensity score can reduce bias relative to the models that use only a predefined group of variables. 24, 27, 30 Therefore, we supplemented a defined set of a priori confounders with additional covariates for all medical conditions and drugs. The known confounders were age, gender, state, quarter of the year of the index date, year, time in the database before the index date, major depression, mood disorders, anxiety disorders, abuse of nonopioid medications (such as alcohol or tobacco), and use of benzodiazepines. The ICD-9 codes used to define these conditions are listed in Appendix 2. In addition, binary covariates were added for each medical condition, based on a diagnosis of the condition in the prior 3 months, as represented by the 227 unique high level group terms with the Medical Dictionary for Regulatory Activities (MedDRA) vocabulary (eg, coronary artery disorders). Eighty-two covariates were also included for each drug class, as represented by 2-digit codes within the Anatomical Therapeutic Chemical classification system (eg, diuretics) if any drug within the class was dispensing during the 3 months prior to the index date. The Observational Medical Outcomes Partnership vocabulary was used to map ICD-9 codes to MedDRA high level group terms and National Drug Codes into Anatomical Therapeutic Chemical classification.
14,28,34 Major depression, mood and anxiety disorders, and abuse of nonopioid medications, such as alcohol or tobacco, and pain-related diagnoses were not mapped to MedDRA concepts to allow for more specificity. Pain diagnoses were included as arthritis, back pain, fractures, headache, malignancies, musculoskeletal pain, neuropathic pain, other, reproductive system pain, visceral pain, and wound/injury using published ICD-9 groupings.
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The propensity score was estimated using Bayesian logistic regression. 18 We used a Laplace distribution for the prior and cross validation to obtain the variance.
Checking Balancing Properties of the Propensity Score
To check the balancing properties of the propensity score, we tabulated the pain-related conditions and the other variables known to be associated with opioid abuse in each treatment group and calculated standardized differences of means or proportions in each of the quintiles of the propensity scores and overall. To calculate the overall standardized difference for each potential confounder, we averaged the standardized differences of the propensity score quintiles for that potential confounder. Standardized differences of less than .25 are an indication of appropriate balance.
33

Outcome Model
The relative risk of opioid abuse between tapentadol and oxycodone was estimated using a logistic regression model, with the binary indicator of incident opioid abuse diagnosis as the outcome variable and the exposure status and propensity score quintiles as covariates. The estimates from the 2 databases were then pooled using a random effects model. Odds ratios (ORs) and 95% confidence intervals (CIs) are reported. For outcomes of low frequency, as is the case with abuse, odds closely approximate risks, so we refer to the more familiar term, risk. Oxycodone was used as the referent group such that ORs <1 indicate a lower risk of an abuse diagnosis with tapentadol.
Dose Assessment
Daily dose of opioid at baseline was calculated and to allow comparison converted into tapentadol equivalent doses using a 5:1 conversion ratio.
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Sample Size
Approximately 1,000 subjects initially exposed to tapentadol were needed to detect a 2-fold decrease in the risk of abuse, assuming a 3% risk of abuse among those who were initially exposed to oxycodone, 15 with 80% power, an alpha error of 5%, and a ratio of oxycodone to tapentadol subjects of 10:1.
Sensitivity Analyses
We evaluated the robustness of the propensity score model by performing the analysis with and without Figure 1 . Flow diagram in Optum database. Numbers represent subjects who failed to meet each one of the inclusion criteria.
The percentages use the number of exposed patients as denominators.
trimming of patients with nonoverlapping propensity scores. 34 We also performed matching as an alternative propensity score adjustment strategy to stratification. We implemented a nearest available matching algorithm with a 1:1 tapentadol to oxycodone ratio in the Optum database and, because of the larger sample size, a 1:2 match in the MarketScan database, and a propensity score difference smaller than .1. We then built a conditional logistic regression to obtain the relative risk of opioid abuse diagnosis between tapentadol and oxycodone while respecting the matches.
The analyses were conducted using SAS, version 9.3 (SAS Institute Inc, Cary, NC). The New England Institutional Review Board determined that this study was not human subjects research and was exempt from review.
Results
There were 13,814 subjects from the Optum database who met the inclusion criteria (11,378 initially exposed to oxycodone, 2,436 to tapentadol) and 25,553 subjects from the MarketScan database who met the inclusion criteria (21,728 initially exposed to oxycodone, 3,825 to tapentadol). Figs 1 and 2 show the number of subjects who failed to meet each one of the inclusion criteria in each of the databases.
In each database, subjects in the tapentadol group were older, more likely to be women, and more likely to have back pain than subjects in the oxycodone group (Table 2) .
The daily dose of opioid at baseline was slightly higher in the tapentadol group than in the oxycodone group in both databases. The median tapentadol equivalent daily dose in the tapentadol group was 300.0 mg versus 250.0 mg in the oxycodone group in the Optum database and 300.0 mg versus 214.3 mg in the MarketScan database. There was no observed difference in other opioid use between the tapentadol and oxycodone groups, and the majority of persons in each cohort had no other opioid use (25th-75th percentile, 0-2).
The models to calculate the propensity score included 365 variables in the Optum database and 370 variables in the MarketScan database. After stratification on the propensity score, most standardized differences in baseline characteristics got smaller ( Table 2 ), indicating that a better balance was achieved. Similarly, the standardized differences for each one of the confounders in each one of the quintiles of the propensity score were very small, especially in the first 4 propensity score categories in each database, confirming the good balance achieved with the propensity score (Appendixes 3 and 4).
In each database, a higher percentage of subjects in the oxycodone group than in the tapentadol group received opioid abuse diagnoses. After adjustment, the risk of developing an opioid abuse diagnosis remained The percentages use the number of exposed patients as denominators. higher in the oxycodone group than in the tapentadol group in each database (Table 3) . Overall, the risk of developing abuse diagnoses was much smaller with tapentadol than with oxycodone (pooled estimate for abuse, OR = .35, 95% CI = .21-.58; Fig 3) . The sensitivity analyses provided similar results to the main analyses. After excluding subjects without complete propensity score overlap, 10,111 subjects initially exposed to oxycodone and 2,434 subjects initially exposed to tapentadol in the Optum database and 19,013 subjects initially exposed to oxycodone and 3,806 subjects initially exposed to tapentadol in the MarketScan database were included in the analyses. The standardized differences in each of the quintiles of the propensity score were similarly small compared with the ones in the main analysis. As in the main analyses, the risk of developing an abuse diagnosis was much smaller in subjects exposed to tapentadol than in subjects exposed to oxycodone in each database (Table 3) .
The results after matching were similar to the main analyses as well. In the Optum database, a total of 4,018 subjects were matched, half initially exposed to tapentadol and half to oxycodone. In the MarketScan database, 5,817 subjects were matched, 1,939 initially exposed to tapentadol and 3,878 to oxycodone. The risk of developing an abuse diagnosis was much smaller with tapentadol than with oxycodone in each of the databases: OR = .20, 95% CI = .08-.54, in the Optum database and OR = .33, 95% CI = .14-.79, in the MarketScan database.
Discussion
The odds of receiving an abuse diagnosis among those who initiated opioid use with tapentadol IR was 65% lower than the risk of receiving an abuse diagnosis among those who initiated opioid use with oxycodone IR. The fact that the risk of receiving an abuse diagnosis with tapentadol was similarly low in the 2 claims databases and that the results remained similar in the sensitivity analyses provide confidence in the findings of the study. The relatively low affinity of tapentadol for the mu-opioid receptor may explain its lower abuse risk.
The observed lower risk of receiving an abuse diagnosis associated with tapentadol in this study aligns with its lower risk of opioid doctor shopping behavior.
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A retrospective cohort study in a longitudinal prescription database compared the risk of opioid doctor shopping behavior between opioid-na€ ıve patients who initiated opioid use with tapentadol IR and those who initiated with oxycodone IR and found that the risk of opioid doctor shopping (subjects with overlapping opioid prescriptions written by different prescribers and filled at $3 pharmacies) was 72% lower in subjects exposed to tapentadol than in subjects exposed to oxycodone (OR = .28, 95% CI = .22-.35). 9 The relative reductions in the risks of opioid doctor shopping behavior and receiving an opioid abuse diagnosis are of similar magnitude. The results of the present study also align with data from pharmacovigilance studies, which suggest a lower risk of abuse.
11 One of these studies included an assessment of the street price of tapentadol, which was found to be one-tenth the street price of oxycodone on a per-milligram basis, 37 or half the street price of oxycodone after adjustment for potency. These overall findings provide reassurance that the lower risk of receiving an abuse diagnosis of tapentadol is neither the result of a peculiarity of a particular database nor the endpoint assessed.
The findings of lower risks of shopping behavior and receiving an abuse diagnosis associated with tapentadol are in contrast with results of a likeability study that showed that in opioid-experienced individuals, the subjective effects of tapentadol were comparable to the subjective effects of oral hydromorphone, and with animal data studies that showed that tapentadol exhibited rewarding and reinforcing effects that were similar to the ones produced by other opioids. 22 The different contexts in which these studies were performed, and the different types of subjects included in these studies, may contribute to the disparity of their findings.
Tapentadol IR was launched in 2009 and has been on the U.S. market for much less time than oxycodone IR. It could be argued that there might have not been enough time for abusers to experiment with tapentadol. Data from the Researched Abuse, Diversion and AddictionRelated Surveillance, a surveillance system that monitors the abuse, misuse, and diversion of prescription opioids, suggest that abuse can be seen very soon after a new opioid is marketed.
13 Nonetheless, definitive proof for the lower risk of abuse of tapentadol will need to await longer experience with tapentadol because the desirability of an opioid can change over time.
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Limitations
The ICD-9 codes we used to define abuse diagnosis included codes for opioid dependence as well as abuse. Opioid dependence does not necessarily imply abuse. Opioid abuse has been defined as the use of an opioid for psychic effects or any harmful use of the opioid. 42 In contrast, opioid dependence is a state of adaptation that is manifested by withdrawal syndrome, diminution of the analgesic effect over time (tolerance), or dose escalation. 1, 4, 29, 42 However, many physicians use the terms ''opioid abuse,'' ''opioid addiction,'' and ''opioid dependence'' interchangeably, and other studies that have assessed opioid abuse combined the codes as well. 15, 16 Despite the fact that the codes for abuse and dependence are combined, opioid abuse is likely to be underascertained in claims databases. Potential reasons for underrecording of abuse include lack of recognition of the condition; reluctance to put a potentially damaging diagnosis in the patient's record, especially in the absence of certainty; and, because claims databases were developed to facilitate commercial transactions, the fact that reimbursement considerations could affect which diagnosis codes to use.
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The incidence of opioid abuse diagnosis in our study was .6%. Though similar to the incidence reported in other claims database studies, 41 this abuse rate is more than 10 times lower than what has been reported in past prospective studies (range, 5-31%). 23, 38 In our current study, we observed an absolute risk reduction of #.5%. If the true incidence of abuse is in fact 10 times higher, then the impact on the absolute risk reduction could be 10 times greater. In contrast, as long as the underreporting is similar in the 2 groups, the extent of underestimation does not bias the odds ratios reported in our study.
The findings of this study represent a privately insured population and therefore may not generalize to other populations of interest, such as the elderly or the uninsured.
Physicians prescribed tapentadol or oxycodone to the patients for clinical indications, and therefore patients were not randomized. We controlled for the effect of potential confounders through propensity score adjustment, which permits the inclusion of a large number of confounders. The balancing properties of the propensity score are well known, but limited to the confounders included in the models. Therefore, unobserved baseline differences cannot be ruled out and those differences could explain the results.
In summary, subjects who initiated opioid treatment with tapentadol IR had a lower risk of receiving an opioid abuse/dependence diagnosis than subjects who initiated opioid treatment with oxycodone IR. However, the risk with tapentadol IR is not absent. Opioid prescribers and patients must be aware of the risk of abuse associated with all opioids and of changes in opioid desirability over time. Abbreviation: PS, propensity score.
